Reading this on a mobile device? Try our optimized mobile version here:

October 29, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Health M&A could increase in 2013, analysts say
    Health companies have large cash reserves, and drugmakers are shifting their focus from cost-cutting to filling pipelines through mergers and acquisitions, industry analysts say. Next year could top the 2,076 health deals worth $166 billion announced in the past 12 months. "What tends to drive that is the need. There's clearly a need for larger companies who are facing patent cliffs and whose own R&D machines have not panned out, to find growth," he said. Bloomberg (10/25) LinkedInFacebookTwitterEmail this Story
New Technologies Give Older Drugs a Makeover
The disappointing returns on biopharmaceutical research and development, despite the availability of advanced molecular technologies and the investment of billions of dollars, is forcing companies to re-evaluate their business plans. One idea that is coming back into vogue again is the strategy of giving older drugs a makeover. Find out the details.

  Health Care & Policy 
  • Avedro gains access to EyeGate ophthalmic drug patents
    EyeGate Pharmaceuticals granted Avedro rights to use patents relating to its investigational drug EGP-437, which is under development for uveitis and dry eye syndrome. EyeGate CEO Stephen From said Avedro will use the patents to develop a possible treatment for the orphan eye disease keratoconus. Mass High Tech (Boston) (10/26) LinkedInFacebookTwitterEmail this Story
  • OncoMed contracts Lonza to manufacture cancer drugs
    Lonza will develop and manufacture OncoMed's pipeline of experimental stem cell treatments for cancer. The deal covers OncoMed's demcizumab, anti-Notch, anti-Notch 2/3, anti-Fzd7, anti-DLL4/VEGF treatments and other monoclonal antibodies. "This multi-product contract and GS license agreement demonstrate Lonza's ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product life cycle," said Stephan Kutzer, chief operating officer custom manufacturing at Lonza. Pharmaceutical Business Review Online (10/26) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • BP ends plans for Fla. cellulosic-ethanol project
    BP is dropping its proposed $300 million cellulosic-ethanol plant project in Highlands County, Fla., the company said. BP will focus its U.S. biofuels efforts on technology licensing and research and development. "In order to make the large capital investments necessary to commercialize advanced and cellulosic biofuels, companies need to know that the U.S. is committed to achieving energy security and that the Renewable Fuel Standard is here to stay," said BIO Executive Vice President Brent Erickson. (10/26), Bloomberg Businessweek (10/25) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Being inexhaustible, life and nature are a constant stimulus for a creative mind."
--Hans Hoffman,
German-American abstract expressionist painter

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information